07 August 2017
Visiongain has launched a new pharma report Smart Pill Market World Market Forecast 2017-2027: See Prospects for Capsule Endoscopy, Drug Delivery and Patient Monitoring in North America, South America, Europe, Asia-Pacific and the Rest of the World
Smart Pill technology is a revolutionary technological innovation that has bridged the gap between healthcare and digital technology. Smart Pills are basically medical devices and small embedded electronic appliances such as sensors, cameras and trackers. This electronic device can be easily swallowed and it also provides complete evaluation of the gastrointestinal tract (GIT).
The emergence of these ‘healthcare-cum-technology’ devices has addressed the soaring need for better diagnostics and monitoring. It has outperformed the conventional GI monitoring endoscopy with more convenient Smart Pill technology, which has now become the standard non-invasive diagnosis technique for motility disorders. Moreover, it helps physicians in real-time patient monitoring through remote controlling options.
The lead Visiongain report analyst for this report commented; “The Value Chain of the Smart Pill technology market includes different stakeholders such as Raw material suppliers, Manufacturers, Suppliers/distributers, Service providers, and Payers (Hospitals and clinics). Each stakeholder plays a different role and the activities indicate the direct influence that production processes have on the Smart Pill technology market. The functioning of primary activities is supplemented by supporting activities without any disruption in the production process. These support activities in the Smart Pill technology include technological advancements, patent protection, research and development activities along with government regulations and reimbursement. Primary and secondary activities are greatly influenced by external stakeholders such as suppliers, end-users and payers (Hospitals and clinics).
However, clinicians, doctors and gastroenterologist sometimes prefer traditional endoscopy procedures due to its comparatively lower cost than capsule endoscopy systems. Moreover, in under developed regions like Africa, doctors for the sake of patient’s affordability mostly prefer traditional endoscopy techniques. However, the diagnostic results offered by the capsule endoscopy technique is far better than traditional endoscopy techniques, thus, the smart pill market is expected to increase significantly in size over the forecast period”
The Smart Pill Market World Market Forecast market is highly competitive with many different players entering the market. The report discusses selected leading companies in the market. Notable companies in the global smart pill market Cerner Corporation,
GE Healthcare, Proteus Digital Health Inc, Boston Scientific Corporation, Capso Vision Inc., Fujifilm Holdings Corporation, Medtronic PLC, Bio-Image Drug Delivery Limited (BDD), Hoya Corporation (PENTAX Medical) and Olympus Corporation.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Global Genome Editing Technologies market is estimated to be valued at US$ 4,225.48 million in 2022. The market is projected to reach a market value of US$ 18,570.41 million by 2032. We predict strong revenue growth through to 2032.
02 August 2022
The global synthetic biology market was valued at US$13.8 billion in 2021 and is projected to grow at a CAGR of 25.52% during the forecast period 2022-2032.
27 July 2022
The global biosimilar monoclonal antibodies market was valued at US$4,087 million in 2021 and is projected to grow at a CAGR of 23.5% during the forecast period 2022-2032.
25 July 2022
The global drug discovery services market is anticipated to be valued at US$14.17 billion in 2022 and is projected to grow at a CAGR of 15.17% during the forecast period 2022-2032.